Natural product therapy targeting aberrant Lipid synthesis in Human cancers: Thymoquinone, isolated from Monarda Fistulosa, suppresses the expression of the principal enzyme in lipid synthesis, ACLY, inhibits aberrant lipid production, and tumor progression via up-regulation of its target gene, 26/October/2016, 6.00 am

Natural product Lifespan extension therapy: Green tea extract increases life span via up-regulation of its target gene BubR1, 25/October/2016, 9.01 am
October 25, 2016
Natural product therapy for brain repair and Life-span extension: Resveratrol, an activator of longevity promoting gene Sirtuin-1, increases VGF and BDNF expression, promotes Oligodendrocytes (OP) proliferation, triggers myelination on neurons, reverts neural damage, produces anti-depressant like effects, and prolongs lifespan via up-regulation of its target gene, 26/October/2016, 7.10 am
October 26, 2016
Show all

A recent study from Rutgers Cancer Institute of New Jersey, Rutgers University, The State University of New Jersey, New Brunswick, New Jersey, USA shows that “Cullin3–KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression.” This study was published in the 1 September  2016 issue of Genes Development  by Prof Feng Z, Zhang C, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product therapy targeting aberrant Lipid synthesis in Human cancers: Thymoquinone, isolated from Monarda Fistulosa,  suppresses the expression of the principal enzyme in lipid synthesis, ACLY,  inhibits aberrant lipid production, and tumor progression via up-regulation of its target gene


Significance:

Given that cancer causes the highest economic loss compared to all the known causes of human death worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug that targets abnormal bio-fuel requirements of cancer cells; (iii) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (iv) a way to effectively treat and eradicate metastatic progression of cancer.

Thymoquinone, isolated from Monarda Fistulosa, inhibits aberrant lipid biosynthesis in cancer cells via down-regulation of ACLY

Thymoquinone, isolated from Monarda Fistulosa, inhibits aberrant lipid biosynthesis in cancer cells via down-regulation of ACLY

Thymoquinone or its analogue may

Thymoquinone

This study suggests, for the first time, that Thymoquinone, by increasing the expression of its target gene, it may suppress the expression of ATP-Citrate lyase (ACLY). Remarkably, a number of human tumors overexpress ACLY, suggesting that inhibition of its activity may inhibit aberrant lipid synthesis in cancer cells, and thereby increase the efficacy of anticancer therapy.

Thus, pharmacological formulations encompassing “Thymoquinone or its analogs may be used to treat human cancers that specifically overexpress ACLY.


Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To cite: Boominathan, Natural product therapy targeting aberrant Lipid synthesis in Human cancers: Thymoquinone, isolated from Monarda Fistulosa, suppresses the expression of the principal enzyme in lipid synthesis, ACLY,  inhibits aberrant lipid production, and tumor progression via up-regulation of its target gene, 26/October/2016, 6.00 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Amount: $300#

satisfaction-guarantee

Results guaranteed if not refunded

Undisclosed information: How Thymoquinone inhibits the expression of ACLY?

Comments are closed.